Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.
Newsletter & e-edition
News, trends and background information as well as the latest issue of CHEManager International
